Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.3998
- Book/Share 17.2615
- PB 8.2682
- Debt/Equity 1.1579
- CurrentRatio 1.4535
- ROIC 0.1755
- MktCap 177764576383.0
- FreeCF/Share 7.3709
- PFCF 19.4024
- PE 21.9602
- Debt/Assets 0.4261
- DivYield 0.0221
- ROE 0.407
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GILD | UBS | -- | Buy | -- | $145 | Jan. 7, 2026 |
| Resumed | GILD | Truist | -- | Buy | -- | $140 | Nov. 24, 2025 |
| Initiation | GILD | Scotiabank | -- | Sector Outperform | -- | $140 | Nov. 13, 2025 |
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
News
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's Why Gilead Sciences Stock Surged 21% in a Month
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.
Read More
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
Published: January 20, 2026 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Livdelzi, drive incremental growth and diversification. Q3 2025 results exceeded expectations, with revenue up 4% YoY and non-GAAP EPS up 22%, highlighting strong operational efficiency and margin expansion.
Read More
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. GILD guides for 2025 sales of $28.4–$28.7 billion and EPS of $8.05–$8.25, with HIV revenue forecast above $20B and a strong pipeline.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
Published: January 12, 2026 by: CNBC Television
Sentiment: Positive
Daniel O'Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication, drug pipeline outlook, impact of AI, and more.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Cash-Flow Machines Investors May Want Heading Into 2026
Published: January 02, 2026 by: MarketBeat
Sentiment: Neutral
Of the host of financial metrics investors might consider when deciding whether to buy shares of a target company, cash flow is among the most important. Operating cash flow is a reflection of how a firm actually functions on a day-to-day basis and demonstrates the company's ability to bring in money from sales or other sources and to adequately pay salaries, taxes, and other expenses.
Read More
GILD Exercises Option to License Assembly Bio's Herpes Programs
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R.
Read More
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company's long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O'Day, C.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
Read More
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
Read More
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains
Published: December 15, 2025 by: MarketBeat
Sentiment: Positive
Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize efficiency. In this environment, it can be particularly challenging for firms to maintain cash flow, which is vital to their continued healthy operations and growth.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. ( GILD ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Thanks so much for attending the Jefferies Healthcare -- London Healthcare Conference. It's already day 3.
Read More
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livin.
Read More
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Read More
Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. ( GILD ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good morning, everyone. My name is [ Dina Elmonshed.
Read More
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel O'Day
- Employees 17600